Salute e Benessere
Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight
Discover the osteosarcoma new treatment @
The osteosarcoma market dynamics are expected to change in the coming years. Improvement of treatment over the years, along with , the investigation of various immunotherapies such as , and the exploration of genetic and other underexplored disease-related biomarkers may bring a positive shift in the management of osteosarcoma, while the and maintenance therapy provides opportunities for pharmaceutical companies to enter the market.
As potential therapies are being investigated for the treatment of osteosarcoma, it is safe to predict that the treatment space will significantly impact the osteosarcoma market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the osteosarcoma market in the 7MM.
However, several factors may impede the growth of the osteosarcoma market. Around half of osteosarcoma patients during treatment, and the disease is further challenged by a for relapsed or refractory cases, complications from current treatments such as low survival rates in older patients and adverse effects, in late-phase clinical trials, and a low patient population for conducting clinical studies.
Moreover, osteosarcoma treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the osteosarcoma market growth may be offset by , , , and a . In addition, the about the disease may also impact the osteosarcoma market growth.
The standard treatment for osteosarcoma typically combines surgery, chemotherapy, and, in some cases, radiation therapy. Surgery focuses on removing the tumor while maintaining maximum function and mobility, often through limb-sparing procedures, though amputation may sometimes be necessary. In pediatric patients, rotationplasty can be an option. Chemotherapy is administered both before surgery to reduce tumor size and after surgery to destroy residual cancer cells. Commonly used chemotherapy agents include cisplatin, doxorubicin, ifosfamide, and high-dose methotrexate. Radiation therapy is less frequently employed but may be considered when surgery is not feasible or for palliative purposes.
Currently, is the only approved therapy for osteosarcoma. It is specifically indicated for high-grade, non-metastatic osteosarcoma in patients aged 2 to 30 years following complete surgical removal of the tumor and is used in combination with post-operative multi-agent chemotherapy. In March 2009 , the European Commission granted marketing authorization for MEPACT across the EU to IDM Pharma, which was later acquired by Takeda in the same year. However, MEPACT is not approved in the United States . Still, some patients in the US have accessed it through the FDA's compassionate use and personal importation programs.
To know more about FDA-approved drugs for osteosarcoma, visit @
The emerging pipeline drug for osteosarcoma includes (OS Therapies), (MedPacto), (Hutchmed), and others.
is a monoclonal antibody targeting GD2, developed by researchers at Memorial Sloan Kettering Cancer Center (MSK) and exclusively licensed to Y-mAbs Therapeutics. This drug acts against the human tumor-associated antigen GD2 and exhibits potential antitumor activity. By binding to GD2, naxitamab triggers antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing this antigen.
is a biologic therapeutic candidate utilizing an off-the-shelf Listeria monocytogenes (Lm) vector-based immunotherapeutic vaccine platform, designed to prevent metastasis, delay recurrence, and improve overall survival in osteosarcoma patients. The company reported positive Phase IIb AOST-2121 clinical trial results in June 2024 , and by October 2024 , the final patient had been enrolled.
The drug has received from both the FDA and the European Medicines Agency (EMA), as well as from the FDA and from the EMA. It has also been awarded by the FDA. Under the RPDD program, if accelerated approval is obtained before September 30, 2026 , the company will be eligible for a Priority Review Voucher (PRV), which it plans to sell.
The anticipated launch of these emerging therapies are poised to transform the osteosarcoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the osteosarcoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about osteosarcoma marketed and pipeline drugs @
Osteosarcoma is the most common type of primary bone cancer, predominantly affecting children, teenagers, and young adults. It originates in the osteoblast cells responsible for bone formation and typically arises in the long bones, such as the femur, tibia, or humerus, near the growth plates. While the exact cause of osteosarcoma is not fully understood, genetic mutations, inherited cancer syndromes, previous radiation therapy, and rapid bone growth during adolescence are considered major risk factors.
The symptoms of osteosarcoma often begin subtly and may include persistent localized bone pain, which tends to worsen at night or during activity. Swelling, tenderness, or the appearance of a lump near the affected bone is common, along with restricted movement of nearby joints. In advanced stages, fractures can occur due to weakening of the bone.
Diagnosis involves a combination of imaging tests and biopsy. X-rays, MRI, and CT scans are commonly used to evaluate bone structure and detect tumor spread, while PET scans help assess metastasis. A definitive diagnosis is made through a biopsy, where a tissue sample is examined microscopically to confirm cancerous cells. Blood tests, though not diagnostic, may support evaluation by indicating markers like elevated alkaline phosphatase or lactate dehydrogenase (LDH).
The osteosarcoma epidemiology section provides insights into the historical and current osteosarcoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The osteosarcoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Download the report to understand which factors are driving osteosarcoma treatment market trends @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key osteosarcoma companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Ewing sarcoma companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key STS companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chondrosarcoma companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo : https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/osteosarcoma-market-on-the-rise-in-the-7mm-during-the-forecast-period-20252034-with-novel-therapeutics-and-technological-innovations--delveinsight-302517049.html